Mycophenolate mofetil treatment in patients with limited cutaneous systemic sclerosis is linked to a reduced need for escalation of vasoactive or vasodilator therapies for vascular complications.

Please provide your email address to receive an email when new articles are posted on . Adding mycophenolate mofetil to a glucocorticoid in first-line treatment for immune thrombocytopenia improves ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving mycophenolate mofetil combination therapies saw increased seroconversion after a third dose ...

The use of mycophenolate mofetil (MMF) for prophylaxis of aGVHD and/or for treatment of acute or chronic GVHD is increasing. However, the benefit of MMF as an alternative to commonly used ...

Purpose: The pharmacology, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, monitoring, and dosage and administration of enteric-coated (EC) mycophenolate sodium are reviewed.

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis. A ...

Triple-drug immunosuppression regimens including mycophenolate mofetil, taken for ≥6 months are associated with reduced rates of LAR; further studies are needed to define optimal immunosuppression ...

Credit: Azurity Pharmaceuticals. Myhibbin is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection. Myhibbin is expected to be commercially available in the second ...

A phase 3 trial explored which treatment option for pemphigus vulgaris, a rare skin disease, resulted in better outcomes after 52 weeks. In patients with pemphigus vulgaris, rituximab was superior to ...

The addition of mycophenolate mofetil (MMF) to a glucocorticoid as a first-line treatment for immune thrombocytopenia (ITP) resulted in greater responses and a reduced risk of relapse or refractory ...

To the Editor: There are several reasons to be circumspect with regard to applying more widely the findings of the report by Ginzler et al. that compared cyclophosphamide and mycophenolate mofetil for ...

Up to 40% of patients with IgAN progress to end-stage kidney disease, investigators noted. Mycophenolate mofetil (MMF) reduces the risk of disease progression in patients with immunoglobulin A ...